SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Background. In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alternative. For patients infected with human immunodeficiency virus (HIV-1) virolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Campo, R., DeJesus, E., Bredeek, U. F., Henry, K., Khanlou, H., Logue, K., Brinson, C., Benson, P., Dau, L., Wang, H., White, K., Flaherty, J., Fralich, T., Guyer, B., Piontkowsky, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641864/
https://www.ncbi.nlm.nih.gov/pubmed/23362296
http://dx.doi.org/10.1093/cid/cis1203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641864/
https://www.ncbi.nlm.nih.gov/pubmed/23362296
http://dx.doi.org/10.1093/cid/cis1203

Ejemplares similares